National Multiple Sclerosis Society (NMSS)

Myrobalan Therapeutics is a biotechnology company dedicated to developing oral neurorestorative therapies that target brain dysfunctions and central nervous system (CNS) disorders. The company leverages its deep understanding of neurological processes, including demyelination and neuroinflammation, to identify and develop innovative therapeutic candidates. With a focus on reversing the underlying pathologies of CNS conditions, Myrobalan Therapeutics aims to address significant unmet medical needs. Their dedicated team of scientists employs advanced drug discovery tools to create selective and brain-penetrant therapies, ultimately enabling healthcare professionals to offer new treatment options to a large patient population affected by CNS disorders.

eSupport Health, established in November 2019 as a Delaware Public Benefit Corporation, focuses on enhancing the mental health of individuals living with multiple sclerosis (MS) and other chronic conditions. The company provides professional support groups tailored for those diagnosed with MS, newly diagnosed individuals, and their family members. These groups convene weekly through secure online video sessions, led by experienced coaches who are licensed therapists with expertise in MS. eSupport Health offers the first month of participation free of charge and also hosts free monthly workshops accessible to all registered participants. Through its services, the company aims to deliver practical solutions that foster emotional well-being in a supportive community.

BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD). NurOwn™, our proprietary, first-of-its-kind technology for the propagation and differentiation of autologous Mesenchymal Stem Cells (MSCs) into NeuroTrophic Factor (NTF)-secreting cells and their transplantation at or near the site of damage, offers the hope of conquering neurodegenerative diseases. We are currently conducting a Phase IIa ALS clinical trial with NurOwn at the Hadassah University Medical Center in Jerusalem. In this safety and preliminary efficacy trial, 12 patients will receive combined intramuscular and intrathecal administration of neuron cells in three cohorts with increasing doses. The study participants will be followed for three to six months after transplantation. The company also plans to begin a Phase II clinical trial in the USA in 2013, pending FDA approval. On February 2011, NurOwn was granted Orphan Drug designation by the FDA. Over 20 publications in leading scientific journals demonstrating neuron mechanism of action, pharmacology and in vivo efficacy have been published by the scientific team.

Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, that specializes in developing innovative therapeutics for neurodegenerative diseases and other conditions with unmet medical needs. The company has created a novel drug platform known as Clean-Surface Nanosuspension, which enables the production of clean-surface nanocrystal medicines. This technology supports a pipeline of new drug candidates, particularly targeting demyelinating disorders and oncology. Founded in 2012, Clene Nanomedicine aims to advance treatment options through its unique approach to drug development.

Longevity Biotech, Inc. is a biopharmaceutical company focused on developing innovative therapeutic drug candidates using its proprietary Hybridtide peptide technology. This platform enables the creation of customizable peptides that offer improved stability and absorption, enhancing treatment options for various medical conditions. The company's pipeline includes LBT-3627, a neuroprotective agent aimed at treating disorders such as Parkinson's disease; LBT-6030, a dual agonist targeting glucagon for metabolic conditions; and LBT-5001, a fusion inhibitor. Additionally, Longevity Biotech is conducting clinical studies to identify specific immune and inflammatory markers for the diagnosis of Parkinson's disease. Founded in 2010 and based in Philadelphia, Pennsylvania, Longevity Biotech is committed to advancing drug discovery and development in the biopharmaceutical sector.

NeuroGenesis is a biotechnology company that focuses on developing cell therapies for neurodegenerative diseases. Its primary innovation is the NG CELL™ technology, which uses the patient’s own stem cells to deliver remyelinating and regenerative proteins. This process begins with the collection of bone marrow from the patient, allowing for the neutralization of the stem cell protocol. By maximizing the potential for immunomodulation, neuronal protection, and regeneration, NeuroGenesis aims to enable healthcare professionals to utilize these cells to deliver therapeutic effects directly to affected areas in the brain. The company's approach represents a significant advancement in the treatment of conditions that impact neural health.